LYEL Quote, Financials, Valuation and Earnings

Insmed, Inc. has a net margin of -258973.33% compared to Lyell Immunopharma, Inc.'s net margin of -259.95%. Lyell Immunopharma, Inc.'s return on equity of -86.7% beat Insmed, Inc.'s return on equity of -193.23%.

Lyell Immunopharma, Inc. has a consensus price target of $29.67, signalling upside risk potential of 24.86%. On the other hand Insmed, Inc. has an analysts' consensus of $213.94 which suggests that it could grow by 32.54%. Given that Insmed, Inc. has higher upside potential than Lyell Immunopharma, Inc., analysts believe Insmed, Inc. is more attractive than Lyell Immunopharma, Inc..

Lyell Immunopharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.085, suggesting its more volatile than the S&P 500 by 8.523%.

Lyell Immunopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lyell Immunopharma, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.

Lyell Immunopharma, Inc. quarterly revenues are $15K, which are smaller than Insmed, Inc. quarterly revenues of $142.3M. Lyell Immunopharma, Inc.'s net income of -$38.8M is higher than Insmed, Inc.'s net income of -$370M. Notably, Lyell Immunopharma, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lyell Immunopharma, Inc. is 86,158.63x versus 68.69x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals, Inc. has a net margin of -258973.33% compared to Lyell Immunopharma, Inc.'s net margin of -82.06%. Lyell Immunopharma, Inc.'s return on equity of -86.7% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

Lyell Immunopharma, Inc. has a consensus price target of $29.67, signalling upside risk potential of 24.86%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $90.63 which suggests that it could grow by 18.73%. Given that Lyell Immunopharma, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Lyell Immunopharma, Inc. is more attractive than Ionis Pharmaceuticals, Inc..

Lyell Immunopharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.278, suggesting its less volatile than the S&P 500 by 72.158%.

Lyell Immunopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lyell Immunopharma, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Lyell Immunopharma, Inc. quarterly revenues are $15K, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Lyell Immunopharma, Inc.'s net income of -$38.8M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Lyell Immunopharma, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lyell Immunopharma, Inc. is 86,158.63x versus 13.00x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of -258973.33% compared to Lyell Immunopharma, Inc.'s net margin of -301.29%. Lyell Immunopharma, Inc.'s return on equity of -86.7% beat Nektar Therapeutics's return on equity of -327.67%.

Lyell Immunopharma, Inc. has a consensus price target of $29.67, signalling upside risk potential of 24.86%. On the other hand Nektar Therapeutics has an analysts' consensus of $114.43 which suggests that it could grow by 203.69%. Given that Nektar Therapeutics has higher upside potential than Lyell Immunopharma, Inc., analysts believe Nektar Therapeutics is more attractive than Lyell Immunopharma, Inc..

Lyell Immunopharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.306, suggesting its more volatile than the S&P 500 by 30.624%.

Lyell Immunopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lyell Immunopharma, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Lyell Immunopharma, Inc. quarterly revenues are $15K, which are smaller than Nektar Therapeutics quarterly revenues of $11.8M. Lyell Immunopharma, Inc.'s net income of -$38.8M is lower than Nektar Therapeutics's net income of -$35.5M. Notably, Lyell Immunopharma, Inc.'s price-to-earnings ratio is -- while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lyell Immunopharma, Inc. is 86,158.63x versus 38.85x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -258973.33% compared to Lyell Immunopharma, Inc.'s net margin of 38.89%. Lyell Immunopharma, Inc.'s return on equity of -86.7% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Lyell Immunopharma, Inc. has a consensus price target of $29.67, signalling upside risk potential of 24.86%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $826.04 which suggests that it could grow by 12.69%. Given that Lyell Immunopharma, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Lyell Immunopharma, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Lyell Immunopharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.965%.

Lyell Immunopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.48% to investors and pays a quarterly dividend of $0.88 per share. Lyell Immunopharma, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Lyell Immunopharma, Inc. quarterly revenues are $15K, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Lyell Immunopharma, Inc.'s net income of -$38.8M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Lyell Immunopharma, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lyell Immunopharma, Inc. is 86,158.63x versus 5.67x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.